Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax-Azacitidine in Combination With Chidamide and CAG Versus 3+7 Regimen in Fit Older Patients With Acute Myeloid Leukaemia
NCT07514936Phase 3Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Nov 2024
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of venetoclax, tucidinostat, azacitidine in acute myeloid leukemia (AML), sponsored by Chinese PLA General Hospital. Started Nov 2024; status: recruiting.
02
Drugs
venetoclaxtucidinostatazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07514936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07514936.